title: A preliminary study of recombinant human interferon-α-2a activity against rabies virus in murine model.
abstract: Rabies remains an important public health problem in the world due to uncontrolled enzootic rabies. Although rabies associated fatalities may be prevented with timely immunoprophylaxis, but till date a therapeutic molecule has remained elusive. We investigated the role of rhuIFN α-2a in murine model challenged with rabies virus. Titre of 10(4.25) LD50/0.03 ml of 10% w/v RV CVS stock suspension were obtained. Based on 1LD50 titre, challenge dose of 50 LD 50 was administered along with rhuIFN α-2a with pre-exposure (primed) and post-exposure with the rabies virus. Both showed increased survival time as compared with the virus controls. These findings suggest that the rhuIFN α-2a might have some anti-viral activity, which can be used for the treatment of rabies infection. Further research on the efficacy of interferon along with anti-viral drugs for the treatment will be helpful in designing combination therapy against the disease.
authors.affiliation: Department of Virology, Haffkine Institute, Department of Virology, Haffkine Institute for Training, research and Testing, Aacharya Donde Marg, Parel, Mumbai, Maharashtra - 400 012, India.
authors.forename: S
authors.initials: S
authors.lastname: Roy
authors.forename: D
authors.initials: D
authors.lastname: Patil
authors.forename: S
authors.initials: S
authors.lastname: Ghadigaonkar
authors.forename: R
authors.initials: R
authors.lastname: Roy
authors.forename: S
authors.initials: S
authors.lastname: Mukherjee
authors.forename: A
authors.initials: A
authors.lastname: Chowdhary
authors.forename: R
authors.initials: R
authors.lastname: Deshmukh
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage*; D004195:Disease Models, Animal; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D051379:Mice; D011818:Rabies / Q000188:drug therapy* / Q000821:virology*; D011820:Rabies virus / Q000276:immunology*; D011994:Recombinant Proteins / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins